New EU Filings Include A Range Of First-Of-Their-Kind Therapies
Executive Summary
Pridopidine, sebetralstat and mirdametinib, which are novel treatments that are yet to be approved anywhere in the world, are among the latest products for which marketing applications are now under review by the European Medicines Agency.